Veralto Raised Guidance Twice. The Stock Hasn't Caught Up.

Veralto has raised full-year 2026 guidance twice in three quarters. The stock is still roughly 15% off its 52-week high.

The disconnect isn't a mystery. After Q4 2025 earnings in February, the company beat EPS but issued conservative guidance — flat to low single-digit core sales growth for 2026. The stock dropped 6.2% the next day. That single beat-and-miss set a narrative of a company struggling to accelerate that stuck with investors through Q1 and Q2.

But the narrative has been getting stale since it formed.

Q1 2026 brought 7% total sales growth and $1.07 adjusted EPS — a 21% beat over the $0.88 consensus. Management raised the full-year EPS guidance to $4.20–$4.28 and lifted the core sales growth outlook to 3.0%–4.5%. Then Q2 delivered 7.6% revenue growth, $1.11 adjusted EPS versus a $0.92 estimate, and guidance was raised again — this time to $4.35–$4.43, implying 12%–14% year-over-year EPS growth. Management also said second-half core sales should accelerate to 5%–6%.

The market is still pricing the February disappointment. The operating path has been moving in the other direction for six months.

The number that doesn't bend to a narrative

Free cash flow is the metric that matters most for a business like Veralto. The company — spun off from Danaher in late 2023 — generates roughly $5.5 billion in annual sales, about 60% of which is recurring revenue from consumables, services, and subscription-like contracts. That recurring base is what turns steady operating growth into reliable cash.

Trailing twelve-month free cash flow: $1.05 billion. That's up 11% from a year ago.

The FCF margin has expanded from 15.8% to 18.6% over the same period. That's not a one-quarter jump — it's a sustained improvement driven by operating margin expansion and capital discipline. Capex has stayed around $55–$65 million per year, meaning the company doesn't need heavy reinvestment to keep the business running. Almost every dollar of operating profit flows through.

Q2 alone produced $328 million in free cash flow on $1.47 billion in revenue. At that run-rate, the company is generating roughly $1.3 billion in annual FCF — a number the market hasn't fully absorbed into its valuation.

How the growth is being funded

The company operates through two segments. Water Quality — analytics, treatment, and monitoring for municipal utilities, data centers, power plants, semiconductors, and mining — grew core sales 5.7% in Q2. This is the stronger half, and it's being driven by volume, not just pricing. Industrial water applications now represent roughly half of Water Quality revenue, and management said data centers, power, and semiconductors are providing mid-to-high single-digit growth.

Product Quality and Innovation (PQI) — marking and coding for consumer packaged goods, plus digital packaging and traceability solutions — grew 2.0% in Q2 but management expects meaningful acceleration in the second half from digital workflow adoption and new product launches. PQI has been the drag on the overall growth number, but the trajectory is improving.

The growth story is also being supplemented by acquisitions. Veralto spent roughly $620 million year-to-date on bolt-on acquisitions including In-Situ, GlobalVision, and Alfaa UV. Management has consistently said M&A, not share buybacks, is the primary tool for long-term value creation. They also repurchased about $480 million in shares, bringing total capital deployment to roughly $1 billion year-to-date — all funded from operating cash flow without adding meaningful leverage. Net debt sits at $1.26 billion against $2.12 billion in cash.

What's coming that isn't in the guidance yet

There's an additive element the market can see but can't fully price: a cost optimization program management launched in Q1. The program will cost $85–$105 million upfront but should produce $65–$75 million in annual run-rate savings by 2028. The key detail: almost none of these savings are baked into the 2026 guidance. The CFO called it a "step change" on top of the company's existing 30%–35% earnings fall-through rate from sales growth.

That means the 2026 EPS target of $4.35–$4.43 is being hit before the cost program meaningfully kicks in. If second-half core sales growth reaches the 5%–6% range and the existing fall-through holds, 2027 should show both growth acceleration and margin expansion from the cost savings — without needing any pricing power to sustain it.

The valuation the market has left behind

At $94, Veralto has a market cap of $22.9 billion and an enterprise value of $24.2 billion. The forward P/E sits at 25.7x. That's not cheap by raw multiple standards, and the price-to-forward-FCF of roughly 21x isn't bargain-basement either.

But these multiples are applied to a business with ~60% recurring revenue, an 18.6% FCF margin that's expanding, ROIC around 18%, gross margins near 60%, and a balance sheet that can fund both acquisitions and buybacks from operating cash flow. The cost optimization program should add another 1–2 percentage points of margin by 2028. The pricing moderation management expects in the second half is being offset by volume-led growth.

If second-half core sales reach 5%–6% as management projects and FCF conversion holds above 100%, the company generates roughly $1.1–$1.2 billion in free cash flow for the full year. On that basis, the current EV represents roughly 20–22x forward FCF — which is the multiple territory where a business with Veralto's quality characteristics, recurring revenue profile, and growth trajectory starts to look reasonable rather than expensive.

What would prove the case wrong

The setup depends on second-half execution. Management has said H2 core sales should grow 5%–6%, but this is the first time they've committed to that range. If Q3 core growth comes in at 3% instead of the guided 4%–5%, the acceleration story weakens.

Pricing moderation is also real. Last year's tariff-related price increases are being lapped, and management expects aggregate pricing to come down in the second half. If volume growth doesn't fully offset that moderation, the growth number falls short.

And there's the execution risk around the cost program itself. $65–$75 million in annual savings sounds meaningful — it's roughly 1–2 percentage points of margin — but cost-cutting programs that promise "step changes" have a track record of delivering less than planned or requiring longer than expected to flow through. If 2027 shows only partial savings, the earnings trajectory gets compressed.

China weakness and flat high-growth markets add geographic risk. The Water Quality business in China has been shrinking, and Latin America has experienced project delays. These are small portions of total revenue, but they're worth watching if the broader macro picture deteriorates.

Where it stands

Veralto is not a beaten-down stock. It's a company that disappointed investors with conservative guidance, watched its stock fall, and then spent the next six months steadily proving the guidance was too cautious. Two consecutive raises, $1.05 billion in trailing free cash flow growing 11% year-over-year, and a cost program that hasn't been priced in yet — these are the facts that don't fit the stale narrative.

The stock is 15% off its high. The business trajectory is moving in the opposite direction. Whether that gap closes depends on whether H2 core sales actually accelerate to the 5%–6% range and whether the free cash flow keeps expanding. The FCF bridge is visible. The question is whether the market starts trusting it.